Exploring new frontiers in lung cancer treatment: The role of cancer-associated fibroblasts (CAFs) and EGFR-TKI resistance

Jiaqi Liang; Yidu Hu; Cheng Zhan

doi:10.1002/ctd2.70047

Clinical and Translational Discovery ›› 2025, Vol. 5 ›› Issue (2) : e70047 DOI: 10.1002/ctd2.70047

INVITED LETTER

Exploring new frontiers in lung cancer treatment: The role of cancer-associated fibroblasts (CAFs) and EGFR-TKI resistance

Author information +

History +

PDF

Cite this article

Download citation ▾

Jiaqi Liang, Yidu Hu, Cheng Zhan. Exploring new frontiers in lung cancer treatment: The role of cancer-associated fibroblasts (CAFs) and EGFR-TKI resistance. Clinical and Translational Discovery, 2025, 5(2): e70047 DOI:10.1002/ctd2.70047

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	BrayF, Laversanne M, SungH, et al. Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263.

[2]	HendriksL, RemonJ, Faivre-FinnC, et al. Non-small-cell lung cancer. Nat Rev Dis Primers. 2024;10(1):71.

[3]	ZhangY. Targeting epidermal growth factor receptor for cancer treatment: abolishing both kinase-dependent and kinase-independent functions of the receptor. Pharmacol Rev. 2023;75(6):1218-1232.

[4]	TsuboiM, HerbstRS, JohnT, et al. Overall survival with osimertinib in resected EGFR-mutated NSCLC. N Engl J Med. 2023;389(2):137-147.

[5]	LiangJ, BiG, SuiQ, et al. Transcription factor ZNF263 enhances EGFR-targeted therapeutic response and reduces residual disease in lung adenocarcinoma. Cell Rep. 2024;43(2):113771.

[6]	DaiS, LiuY, LiuZ, et al. Cancer-associated fibroblasts mediate resistance to anti-EGFR therapies in cancer. Pharmacol Res. 2024;206:107304.

[7]	CaligiuriG, Tuveson DA. Activated fibroblasts in cancer: perspectives and challenges. Cancer Cell. 2023;41(3):434-449.

[8]	ChhabraY, Weeraratna AT. Fibroblasts in cancer: unity in heterogeneity. Cell. 2023;186(8):1580-1609.

[9]	ArpinatiL, Carradori G, Scherz-ShouvalR. CAF-induced physical constraints controlling T cell state and localization in solid tumours. Nat Rev Cancer. 2024;24(10):676-693.

[10]	ZhangF, MaY, LiD, et al. Cancer associated fibroblasts and metabolic reprogramming: unraveling the intricate crosstalk in tumor evolution. J Hematol Oncol. 2024;17(1):80.

[11]	XuW, YangH, XuK, et al. Transitional CXCL14+ cancer-associated fibroblasts enhance tumor metastasis and confer resistance to EGFR-TKIs, revealing therapeutic vulnerability to filgotinib in lung adenocarcinoma. Clin Transl Med 2025. accepted.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Discovery published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.